Articles tagged with Pneumonia
A randomized clinical trial demonstrates that rapid molecular testing significantly enhances the speed and accuracy of treatment for community-acquired pneumonia. Patients who received syndromic PCR-based panel testing were three times more likely to receive targeted treatment.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
A special Journal of Intensive Medicine issue explores the latest research findings on ICU infections, prevention strategies, and innovative approaches to sepsis management. The studies shed light on key challenges and advancements in critical care, highlighting the need for personalized treatment methods.
A nationwide cohort study found that COVID-19 survivors exhibit lower all-cause mortality and congestive heart failure but higher acute myocarditis and deep vein thrombosis risks. Younger, non-vaccinated patients with preexisting cardiovascular risk factors face elevated cardiovascular complications.
A study of 345 participants found COVID-19 linked to impaired brain health, with no greater impact than other serious illnesses. Long-term associations suggest brain health tied to overall disease severity and hospitalization.
A systematic review and meta-analysis of 15 clinical trials found daily tooth brushing may reduce hospital-acquired pneumonia rates by up to 50% in high-risk patients. This study suggests that widespread toothbrushing policies could save lives and reduce healthcare costs.
A new study found that daily toothbrushing among hospitalized patients is associated with lower rates of hospital-acquired pneumonia and ICU mortality. The study, which analyzed data from over 2,700 patients, also showed that toothbrushing was linked to shorter durations of mechanical ventilation and ICU length of stay.
Photodynamic action weakens resistance to antibiotics in bacteria that attack airways, reducing the persistence of both standard and clinical strains. The study found that five cycles of PDI were sufficient to break the resistance of resistant bacteria.
Researchers at Osaka Metropolitan University have successfully developed a novel pneumococcal vaccine that demonstrates efficacy in suppressing pneumococcal pneumonia in macaques. The vaccine's design combines proprietary mucosal vaccine technology with pneumococcal surface proteins to cover a wide range of serotypes.
A VA study found that doxycycline use in high-risk pneumonia patients with a prior C. diff infection reduced new infections by 45% compared to azithromycin. Doxycycline's optimal absorption and minimal impact on the gut microbiome may contribute to this effect.
Researchers at the University of Virginia Health System are developing computer models to better understand the cellular processes and gene activity of multi-drug resistant bacteria Staphylococcus aureus and Pseudomonas aeruginosa. The goal is to identify vulnerabilities in these bacteria and advance the development of new treatments.
A University of Melbourne research team is developing an oral therapeutic to restore the activity of common antibiotics used to treat community-acquired bacterial pneumonia. The project aims to combat antibiotic-resistant bacteria and reduce healthcare costs, with potential applications in low- and middle-income countries.
Researchers at the University of Sheffield have discovered a genetic scar that enables pneumonia-causing bacteria to become resistant to antibiotics. The study found that mutations in the pde1 gene act as an evolutionary gateway for this resistance, threatening patient treatment and highlighting the need for control measures.
A study comparing radiologist and AI performance in interpreting 2,000 chest X-rays found that AI tools achieved moderate sensitivity but high false-positive rates. Radiologists outperformed AI in detecting the absence of disease, especially for complex cases.
The 'Crystal Ribcage' technology enables scientists to study lung function at a cellular level while maintaining physiological processes. This innovation holds immense potential for understanding lung diseases and developing new treatments.
A study published in eBioMedicine identified 9 sets of biomarkers, both metagenomic and transcriptomic, associated with 30-day mortality in patients with severe community-acquired pneumonia. The biomarkers were validated with an accuracy of 85%, significantly higher than existing clinical prediction models.
A study led by IBEC analyzed cough sounds in COVID-19 patients to identify the severity of the disease. The research found that acoustic features of coughs could categorize patients as mild, moderate, or severe, enabling early intervention and remote monitoring.
The American Thoracic Society has partnered with five new health systems to identify barriers to vaccination and find ways to improve immunization rates. The initiative aims to increase COVID-19, flu, and pneumonia vaccine uptake among high-risk adults with respiratory diseases.
The study discovered complex microbiome dynamics where commensal and pathogenic microorganisms coexist, influencing the severity of bacterial pneumonia. The respiratory tract microbiome composition, pathogen load, and clinical interventions also play a crucial role in disease outcome.
Researchers developed a deep-learning model to assess CXR images for probable COVID-19 severity. The model achieved an area under the receiver operating characteristic curve of 0.78 when predicting intensive care need within 24 hours.
A new imaging method developed by UC researchers can identify specific lung infections in real time, reducing diagnosis time from 2-3 days to hours. The method uses injectable probes that light up under a nuclear imaging machine, enabling faster treatment for critically ill patients.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
A randomized clinical trial found that treatment with these biologics showed no significant difference in time to recovery compared to placebo for patients hospitalized with COVID-19 pneumonia. The study's results suggest that alternative treatments may be needed for this patient population.
A deep learning-based model developed in 7,105 patients predicted 30-day all-cause mortality in patients with CAP with AUCs ranging from 0.77 to 0.80. The model showed higher specificity than the CURB-65 score at the same sensitivity.
The inaugural issue of CHEST Critical Care focuses on clinically relevant research and patient management guidance for critical care medicine. The journal accepts submissions of original research, case series, and research letters, covering topics such as intensive care medicine and diverse populations.
Researchers found 20 times more potentially pneumonia-causing bacteria on dentures in people with pneumonia than those without. Poorly cleaned dentures may provide a new surface for disease-causing microbes to colonize.
The study analyzed historical data on coal miners in China, revealing a strong correlation between raw coal production, mining technology, and CWP incidence. The researchers identified key turning points in disease incidence, linked to changes in diagnostic criteria and labor management, as well as coal industry policy reforms.
Research found that meeting both recommended weekly physical activity targets was associated with a nearly half the risk of dying from flu or pneumonia as those who met neither. Meeting only the aerobic activity target was linked to a 36% lower risk, while muscle strengthening activities showed no significant difference.
The novel combination antibiotic sulbactam-durlobactam has been found to combat dangerous pneumonia at least as well as the best currently approved treatment. The drug has shown significant tolerability and dosing advantages over existing treatments, making it a promising option for combating hospital-acquired infections.
A new immunotherapy treatment developed by UCF researchers uses targeted IL-2 to fight respiratory viral infections with improved outcomes in animal studies. The treatment promotes an antiviral inflammatory response and reduces bronchial inflammation.
Nearly half of COVID-19 patients develop secondary bacterial pneumonia, which can lead to death. Machine learning analysis found that this complication offsets the mortality rate from the viral infection itself.
A study by University of Alabama at Birmingham researchers reveals that cadmium-induced inflammation increases the severity and mortality of lung infections. The findings suggest that targeting the regulation of PPAR-gamma in macrophages may protect against severe pneumonia.
The American Roentgen Ray Society presents its 2023 Honorary Lecture on Advanced High-Resolution CT, dedicated to the late Dr. W. Richard Webb, who transformed thoracic imaging with his foundational work in HRCT. The lecture explores multiple conditions diagnosed via HRCT and the radiologist's role on multidisciplinary teams.
Researchers from NUS Medicine discovered that specific CPS structures and sugar combinations help Streptococcus pneumoniae colonize the human respiratory tract. The study sheds light on the importance of CPS structure in bacterial survival, which will inform future vaccine development.
The CHEST journal April issue features cutting-edge research on asthma, chronic obstructive pulmonary disease (COPD), and sarcoidosis. Key findings include the potential of efzofitimod as a treatment for managing sarcoidosis. The journal also showcases innovative approaches to clinical practice and education in chest medicine.
A randomized clinical trial found that anakinra did not prevent mechanical ventilation or reduce mortality risk in hospitalized patients with severe COVID-19 pneumonia. Future research is needed to assess anakinra in less severe cases.
Researchers discovered that fomepizole, an FDA-approved drug, can significantly reduce disease in mice infected with multidrug-resistant Streptococcus pneumoniae. The combination of fomepizole and erythromycin reduced bacterial burdens by 95% in the lungs and up to 700-fold in other organs.
Researchers found that fomepizole blocked energy production in bacteria and reduced bacterial burden in mice with pneumonia. The combination treatment prevented invasive disease development, suggesting a potential novel treatment for multidrug-resistant pneumococcal disease.
Contracting a lower respiratory tract infection in early childhood is associated with a higher risk of dying from respiratory disease as an adult. Children who had a LRTI by age two were almost twice as likely to die prematurely in adulthood.
Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...
Researchers have characterised the mutually beneficial relationship between Klebsiella pneumoniae and Acinetobacter baumannii, two pathogens responsible for severe infections. This relationship enables Klebsiella to survive in higher antibiotic concentrations, making it more deadly and resistant to treatment.
A study by University of Liverpool researchers reveals how a unique subset of lung T regulatory cells provide resistance to bacteraemic pneumonia. These cells, known as TNFR2 expressing Tregs, play a critical role in maintaining and controlling frontline host immune responses when pneumococci infect the lungs. The findings have signifi...
A recent study published in the Journal of the American Geriatrics Society found that COVID-19 is associated with higher mortality rates compared to bacterial and viral pneumonia among older patients in intensive care units. The study analyzed data from over 11,500 patients aged 70 years and older who were admitted to Dutch ICUs, revea...
Researchers have designed a treatment that uses a modified bacterium to target and dissolve biofilms caused by Pseudomonas aeruginosa, a leading cause of hospital mortality. The treatment has shown significant efficacy in mice, reducing lung infections and doubling survival rates.
The January issue of the CHEST journal features a range of clinically relevant research on COPD, bronchiectasis, and pulmonary vascular disease. The journal's education portal offers continuing medical education (CME) credit for select articles.
The American Thoracic Society will host ATS 2023 in Washington, DC from May 21-24. The event will cover the latest developments in pulmonary, critical care, and sleep medicine. Register now to attend or access recorded sessions.
Researchers at Charité – Universitätsmedizin Berlin have discovered a cystic fibrosis drug effective in laboratory experiments, raising hope it can treat pneumonia regardless of the pathogen. The study found that CFTR plays a key role in pulmonary edema and that a CFTR modulator, ivacaftor, can prevent this condition.
The December issue of CHEST journal features articles on COVID-19 lessons learned and future pandemic preparedness. The journal also explores various topics in chest medicine, including asthma, critical care, and sleep medicine.
Researchers developed a machine learning algorithm to identify cough sounds and determine if someone has pneumonia, aided by room impulse responses. The algorithm can work in any environment, facilitating non-face-to-face treatment and reducing medical costs.
Researchers found that treatment with remdesivir within 9 days of symptom onset decreases mortality in Japanese patients with severe to critical COVID-19 who received corticosteroids. The study suggests early treatment with remdesivir and corticosteroids is associated with decreased mortality.
Climate change is expanding the geographic range of endemic fungal diseases, such as Valley fever, blastomycosis, and histoplasmosis, which can mimic pneumonia. Physicians are often misdiagnosing these conditions due to a lack of training and limited testing options.
A recent study found that superbugs in the environment rarely transmit to humans, contrary to previous fears. The researchers discovered high levels of antimicrobial-resistant bacteria in livestock, pets, and environmental samples, but surprisingly little overlap between hospital and environmental strains.
Researchers discovered Mycoplasma pneumoniae's lipids spur T cells to overproduce IL-17, leading to neutrophil recruitment and vaccine-enhanced disease. B cells also play a role in modulating the immune response, suggesting they may hold disease in check.
A new treatment option for multi-resistant bacteria has been identified by a UNIGE team, which uses the drug edoxudine to weaken the defence mechanisms of Klebsiella pneumoniae, making it easier to eliminate. This approach could be a game-changer in the fight against antibiotic resistance.
Researchers from McGill University found that pneumococcal vaccination uptake is low among adults at high risk in Canada. Despite the importance of pneumococcal vaccination to prevent pneumonia and other forms of pneumococcal disease, many people missed opportunities for vaccination.
A randomized clinical trial found that applying topical antibiotics to the upper digestive tract can improve survival rates in mechanically ventilated intensive care patients. The study, published in JAMA, also showed a significant reduction in new hospital-acquired infections.
A new study published in the European Respiratory Journal found that early treatment with anti-anaerobic antibiotics can deplete gut anaerobes and lead to worse clinical outcomes. The research suggests that these 'good bugs' protect against pneumonia, organ failure, and mortality.
The October issue of CHEST journal showcases 43 clinically relevant articles on topics such as asthma, COPD, critical care, and sleep medicine. The journal also offers web and multimedia activities, including visual abstracts, to expand its reach.
Researchers observe atomic-level structural changes in bacterial ribosomes and their response to antibiotics, shedding light on mechanisms of action and potential off-target effects. The study provides new insights into the complex interactions between ribosomes and other cellular complexes.
Researchers at the University of California San Diego developed microscopic robots called microrobots that can swim around in the lungs and deliver medication. The microrobots safely eliminated pneumonia-causing bacteria in mice, resulting in 100% survival rates, whereas untreated mice died within three days.